Literature DB >> 25964522

Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.

Carl Blomberg1, Jonas Nilsson1, Georg Holgersson2, Per Edlund3, Michael Bergqvist1, Linda Adwall4, Simon Ekman5, Daniel Brattström5, Stefan Bergström6.   

Abstract

Malignant pleural mesothelioma (MPM) is a rare but aggressive malignancy mainly localized to the pleura. Malignant mesothelioma grows highly invasive into surrounding tissue and has a low tendency to metastasize. The median overall survival (OS) of locally advanced or metastatic disease without treatment is 4-13 months but, during recent years, improvement in survival has been achieved since treatment for patients with mesothelioma has improved with better palliative care, systemic medical treatment, surgery and improved diagnostics methods. The present review aims at describing available data from randomized trials considering systemic medical treatment for this patient category. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Malignant mesothelioma; randomized trials; review

Mesh：

Year:  2015        PMID： 25964522

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  9 in total

1.  Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : A propensity score matching of the SEER database.

Authors:  Omar Abdel-Rahman
Journal:  Strahlenther Onkol       Date:  2017-01-02       Impact factor: 3.621

Review 2.  Current status and progress in immunotherapy for malignant pleural mesothelioma.

Authors:  Boyang Sun; Yiting Dong; Jiachen Xu; Zhijie Wang
Journal:  Chronic Dis Transl Med       Date:  2022-03-31

3.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

4.  Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival.

Authors:  Jennifer L Beebe-Dimmer; Jon P Fryzek; Cecilia L Yee; Tapashi B Dalvi; David H Garabrant; Ann G Schwartz; Shirish Gadgeel
Journal:  Clin Epidemiol       Date:  2016-10-26       Impact factor: 4.790

5.  Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma.

Authors:  Katja Goričar; Viljem Kovač; Vita Dolžan
Journal:  Sci Rep       Date:  2017-04-19       Impact factor: 4.379

Review 6.  New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.

Authors:  Marika Rossini; Paola Rizzo; Ilaria Bononi; Anthony Clementz; Roberto Ferrari; Fernanda Martini; Mauro G Tognon
Journal:  Front Oncol       Date:  2018-04-03       Impact factor: 6.244

7.  Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma.

Authors:  Myung-Chul Kim; Sung-Hyun Hwang; Na-Yon Kim; Hong-Seok Lee; Sumin Ji; Yeseul Yang; Yongbaek Kim
Journal:  BMC Cancer       Date:  2018-08-15       Impact factor: 4.430

8.  Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients.

Authors:  Emanuela Taioli; Andrea S Wolf; Marlene Camacho-Rivera; Andrew Kaufman; Dong-Seok Lee; Daniel Nicastri; Kenneth Rosenzweig; Raja M Flores
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

9.  Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis.

Authors:  Christos Chouaid; Jean Baptiste Assié; Pascal Andujar; Cecile Blein; Charlène Tournier; Alexandre Vainchtock; Arnaud Scherpereel; Isabelle Monnet; Jean Claude Pairon
Journal:  Cancer Med       Date:  2018-02-26       Impact factor: 4.452
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.